JPMorgan lowered the firm’s price target on Conmed (CNMD) to $52 from $58 and keeps a Neutral rating on the shares. The company reported a good Q3 amid “slow and steady” supply and execution improvements, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CNMD: